

IMMUNOGEN INC
Form DEF 14A
October 11, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐

Check the appropriate box:

- ☐ Preliminary Proxy Statement
☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
☒ Definitive Proxy Statement
☐ Definitive Additional Materials
☐ Soliciting Material Under Rule 14a-12

IMMUNOGEN, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- ☒ No fee required.
☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

- ☐ Fee paid previously with preliminary materials.

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

- o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

IMMUNOGEN, INC.

128 Sidney Street, Cambridge, MA 02139 TEL: (617) 995-2500 FAX: (617) 995-2510

October 11, 2002

Dear Shareholder:

You are cordially invited to attend the 2002 Annual Meeting of Shareholders of ImmunoGen, Inc. (the "Company") to be held at 10:00 a.m., Boston time, on Tuesday, November 12, 2002 at the offices of the Company, 128 Sidney Street, Cambridge, Massachusetts.

At the Annual Meeting, six members will be elected to the Board of Directors. In addition, shareholders will vote on a proposal by one of the shareholders of the Company to amend the Company's Restated Articles of Organization to decrease the number of the Company's authorized shares. Your Board of Directors recommends a vote AGAINST the shareholder proposal, for the reasons set forth in this Proxy Statement.

We hope that you will be able to attend the Annual Meeting. Whether you plan to attend the Annual Meeting or not, it is important that your shares are represented. Therefore, you are urged to complete, sign, date and return the enclosed proxy card promptly in accordance with the instructions set forth on the card. This will ensure your proper representation at the Annual Meeting.

Sincerely,

MITCHEL SAYARE
*President, Chief Executive Officer
and Chairman of the Board*

**YOUR VOTE IS IMPORTANT.
PLEASE RETURN YOUR
PROXY PROMPTLY.**

IMMUNOGEN, INC.

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
To Be Held On November 12, 2002

To the Shareholders
of ImmunoGen, Inc.:

NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of ImmunoGen, Inc., a Massachusetts corporation (the "Company"), will be held at the offices of the Company, 128 Sidney Street, Cambridge, Massachusetts, on Tuesday, November 12, 2002 at 10:00 a.m., Boston time, for the following purposes:

1. To elect six members to the Board of Directors to hold office until the next annual meeting of Shareholders and until their successors are duly elected and qualified;
2. To consider and act upon a shareholder proposal to amend the Company's Restated Articles of Organization to decrease from 75,000,000 shares to 50,000,000 shares the aggregate number of shares of Common Stock authorized to be issued by the Company; and
3. To transact such other business as may properly come before the Annual Meeting or any adjournments thereof.

The Board of Directors has fixed the close of business on September 13, 2002 as the record date for the determination of Shareholders entitled to notice of and to vote at the Annual Meeting and at any adjournments thereof.

You are cordially invited to attend the Annual Meeting in person, if possible. **Whether you plan to attend the Annual Meeting or not, please complete, sign and date the enclosed Proxy and return it in the envelope enclosed for this purpose.** Your Proxy is revocable at any time prior to the exercise thereof by written notice received by the Company, by delivery of a duly executed proxy bearing a later date, or by attending the Annual Meeting and voting in person.

By order of the Board of Directors

JONATHAN L. KRAVETZ, ESQ.
Clerk

October 11, 2002

IMMUNOGEN, INC.

128 Sidney Street
Cambridge, Massachusetts 02139
617-995-2500

PROXY STATEMENT

GENERAL INFORMATION

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

This Proxy Statement is furnished in connection with the solicitation by and on behalf of the Board of Directors (the "Board of Directors" or "Board") of ImmunoGen, Inc., a Massachusetts corporation (the "Company"), of proxies, in the accompanying form, to be used at the Annual Meeting of Shareholders to be held at the offices of the Company, 128 Sidney Street, Cambridge, Massachusetts on Tuesday, November 12, 2002 at 10:00 a.m., Boston time, and at any adjournments thereof (the "Meeting").

Where the shareholder specifies a choice on the proxy as to how his or her shares are to be voted on a particular matter, the shares will be voted accordingly. If no choice is specified, the shares will be voted as follows:

FOR the election of the six nominees for Director named herein,

AGAINST the shareholder proposal to amend the Company's Restated Articles of Organization to decrease from 75,000,000 shares to 50,000,000 shares the aggregate number of shares of Common Stock authorized to be issued by the Company.

Any proxy given pursuant to this solicitation may be revoked by the person giving it at any time before its use by delivering to the Company a written notice of revocation or a duly executed proxy bearing a later date. Any shareholder who has executed a proxy but is present at the Meeting, and who wishes to vote in person, may do so by revoking his or her proxy as described in the preceding sentence. Shares represented by valid proxies in the form enclosed, received in time for use at the Meeting and not revoked at or prior to the Meeting, will be voted at the Meeting. The presence, in person or by proxy, of the holders of a majority of the outstanding shares of the Company's Common Stock is necessary to constitute a quorum at the Meeting. Votes of shareholders of record who are present at the meeting in person or by proxy, abstentions, and broker non-votes (as defined below) are counted as present or represented at the meeting for purposes of determining whether a quorum exists. No appraisal rights exist for any action to be taken at the Meeting.

Nominees for election as Directors at the meeting will be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting. Withholding authority to vote for a nominee for Director will have no effect on the outcome of the vote. For the shareholder proposal to amend the Company's Restated Articles of Organization, the affirmative vote of a majority of the shares of Common Stock outstanding and entitled to vote at the Meeting is necessary for approval. Because abstentions are treated as shares present or represented and entitled to vote, abstentions with respect to this proposal have the same effect as a vote against the proposal.

1

If you hold your shares of Common Stock through a broker, bank or other representative, generally the broker or your representative may only vote the Common Stock that it holds for you in accordance with your instructions. However, if it has not timely received your instructions, the broker or your representative may vote on certain matters for which it has discretionary voting authority. If a broker or your representative cannot vote on a particular matter because it does not have discretionary voting authority, this is a "broker non-vote" on that matter. As to the election of Directors, broker non-votes are not deemed to be present and represented and are not entitled to vote, and therefore will have no effect on the outcome of the vote. As to the shareholder proposal to amend the Company's Restated Articles of Organization, which requires the affirmative vote of a majority of the Common Stock outstanding and entitled to vote at the Meeting, broker non-votes have the same effect as negative votes.

The close of business on September 13, 2002 has been fixed as the record date for determining the shareholders entitled to notice of and to vote at the Meeting. As of the close of business on September 13, 2002, the Company had 43,878,488 shares of Common Stock outstanding and entitled to vote. Holders of Common Stock are entitled to one vote per share on all matters to be voted on by shareholders.

The cost of soliciting proxies, including expenses in connection with preparing and mailing this Proxy Statement, will be borne by the Company. In addition, the Company will reimburse brokerage firms and other persons representing beneficial owners of Common Stock of the Company for their expenses in forwarding proxy material to such beneficial owners. Solicitation of proxies by mail may be supplemented by telephone, telegram, telex and personal solicitation by the Directors, officers or employees of the Company. No additional compensation will be paid for such solicitation.

This Proxy Statement and the accompanying proxy are being mailed on or about October 11, 2002 to all Shareholders entitled to notice of and to vote at the Meeting.

The Annual Report to Shareholders for the fiscal year ended June 30, 2002 is being mailed to the Shareholders with this Proxy Statement, but does not constitute a part hereof.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information as of September 13, 2002 concerning the beneficial ownership of the Common Stock by each shareholder known by the Company to be the beneficial owner of more than 5% of the outstanding shares of Common Stock, each current member of the Board of Directors, each executive officer of the Company named in the Summary Compensation Table below, and all current executive officers and Directors of the Company as a group. Except as otherwise indicated, each shareholder has sole voting and investment power with respect to the shares beneficially owned.

Name and Address of Beneficial Owner*	Number of Shares Beneficially Owned (1)	Percentage of Shares Beneficially Owned (1)
Shire BioChem Inc. (2) 275 Armand-Frappier Blvd. Laval, Quebec PQ H7V4A7 Canada	4,096,098	9.3%
Mitchel Sayare (3)	1,000,323	2.3%
Walter A. Blättler (4)	636,812	1.5%
David W. Carter (5)	89,901	**
Michael R. Eisenson (6)		
Mark Skaletsky (7)	44,900	**
Stuart F. Feiner (8)	39,901	**
John M. Lambert (9)	404,325	**
Pauline Jen Ryan (10)	69,167	**
Gregg D. Beloff (11)	18,750	**
Virginia A. Lavery (12)	7,500	**
All current executive officers and Directors as a group (10 persons) (13)	2,311,579	5.3%

*

Addresses are given for beneficial owners of more than 5% of the outstanding Common Stock only.

**

Represents beneficial ownership of less than 1% of the Common Stock.

(1)

The number of shares of Common Stock issued and outstanding on September 13, 2002 was 43,878,488. Share ownership includes shares of Common Stock issuable upon exercise of certain outstanding options and warrants as described in the footnotes below.

(2)

Consists of 4,096,098 restricted shares of Common Stock that Shire BioChem Inc. acquired upon the exercise of warrants on July 29, 2002.

(3)

Includes 764,227 shares of Common Stock which Mr. Sayare may acquire upon the exercise of options within 60 days after September 13, 2002.

(4)

Includes 553,751 shares of Common Stock which Dr. Blättler may acquire upon the exercise of options within 60 days after September 13, 2002.

(5)

Consists of 88,334 shares of Common Stock which Mr. Carter may acquire upon the exercise of options within 60 days after September 13, 2002 and 1,567 stock units granted pursuant to the Company's 2001 Non-Employee Director Stock Plan.

(6)

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

Michael R. Eisenson, a Director of the Company, is President and Chief Executive Officer of Charlesbank Capital Partners, LLC, the successor to Harvard Private Capital Group, Inc. and the

3

investment advisor to Aeneas Venture Corporation ("Aeneas"). Pursuant to an agreement among the Company, Aeneas and Mr. Eisenson, grants of stock and stock options in connection with Mr. Eisenson's service as a Director are granted directly to Aeneas. Pursuant to such grants, Aeneas may acquire 90,000 shares of Common Stock within 60 days after September 13, 2002. Mr. Eisenson owns no shares of Common Stock and disclaims beneficial ownership of the shares owned by Aeneas.

(7) Includes 38,334 shares of Common Stock which Mr. Skaletsky may acquire upon the exercise of options within 60 days after September 13, 2002.

(8) Stuart F. Feiner, a Director of the Company, is Executive Vice President, General Counsel and Secretary of Inco Limited. He is also Chairman of the general partner of North American Partners Limited Partnership II, which owns 19 shares of Common Stock. Mr. Feiner disclaims beneficial ownership of the shares of Common Stock held by North American Partners Limited Partnership II. Includes 38,334 shares of Common Stock that Mr. Feiner may acquire upon the exercise of options within 60 days after September 13, 2002 and 1,567 stock units granted pursuant to the Company's 2001 Non-Employee Director Stock Plan.

(9) Includes 360,034 shares of Common Stock which Dr. Lambert may acquire upon the exercise of options within 60 days after September 13, 2002.

(10) Consists of 69,167 shares of Common Stock which Ms. Ryan may acquire upon the exercise of options within 60 days after September 13, 2002.

(11) Consists of 18,750 shares of Common Stock which Mr. Beloff may acquire upon the exercise of options within 60 days after September 13, 2002.

(12) Consists of 7,500 shares of Common Stock which Ms. Lavery may acquire upon the exercise of options within 60 days after September 13, 2002.

(13) See footnotes (3) (12).

INFORMATION ABOUT THE COMPANY'S DIRECTORS AND CURRENT EXECUTIVE OFFICERS

Under the Company's By-Laws, the number of members of the Company's Board of Directors is fixed from time to time by the shareholders, and Directors serve in office until the next annual meeting of shareholders and until their successors have been elected and qualified. The number of members of the Company's Board of Directors is currently fixed at six. The nominees for the Board of Directors to be elected at the Meeting are Mitchel Sayare, Ph.D., Walter A. Blättler, Ph.D., David W. Carter, Michael R. Eisenson, Stuart F. Feiner and Mark Skaletsky.

4

Set forth below are the names of the persons nominated as Directors, their ages, their offices in the Company, if any, their principal occupations or employment for the past five years, the length of their tenure as Directors and the names of other public companies in which such persons hold directorships.

Name of Director	Age	Principal Occupations During at Least the Last Five Years
Mitchel Sayare	54	

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

Name of Director	Age	Principal Occupations During at Least the Last Five Years
		Mitchel Sayare, Ph.D., Chief Executive Officer, a Director since 1986 and Chairman of the Board since 1989, joined the Company in 1986. From 1986 until 1992, and currently since 1994, Mr. Sayare has served as President of the Company. From 1982 to 1985, Mr. Sayare was Vice President for Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer. From 1977 to 1982, Mr. Sayare was Assistant Professor of Biophysics and Biochemistry at the University of Connecticut. He holds a Ph.D. in Biochemistry from Temple University School of Medicine. Mr. Sayare serves on the Board of Directors of ImmuCell Corporation, in addition to a number of private companies.
Walter A. Blättler	53	Walter A. Blättler, Ph.D., elected a Director in September 1995, served as Vice President, Research and Development of the Company from 1987 to October 1994 and as the Company's Senior Vice President, Research and Development from October 1994 to October 1996. Since 1996, Dr. Blättler has served as the Company's Executive Vice President, Science and Technology. Dr. Blättler joined the Company in October 1987. From 1981 to 1987, Dr. Blättler was chief scientist for the ImmunoGen-supported research program at the Dana-Farber Cancer Institute. Dr. Blättler received his Ph.D. from the Swiss Federal Institute of Technology in Zurich in 1978.
David W. Carter	64	David W. Carter, Lead Director since September 2002 and a Director since June 1997, is Co-Chief Executive Officer and a Director of Xenogen, Inc., which he joined in 1997. From 1991 to 1997, Mr. Carter was the President and Chief Executive Officer of Somatix Therapy Corporation. Mr. Carter also serves on the Board of Directors of Cell Genesys, Inc.
Michael R. Eisenson	47	Michael R. Eisenson, a Director since 1986, is Chief Executive Officer and cofounder of Charlesbank Capital Partners, LLC, which is the investment advisor to Aeneas Venture Corporation, an investment affiliate of the Harvard University endowment fund. From 1986 to 1998, Mr. Eisenson was a Managing Director of Harvard Private Capital Group, Inc., the predecessor to Charlesbank. Between 1981 and 1986, Mr. Eisenson held the position of Manager with the Boston Consulting Group. Mr. Eisenson serves on the Boards of Directors of CCC Information Services Group Inc., Playtex Products, Inc., and United Auto Group, Inc.
5		
Stuart F. Feiner	54	Stuart F. Feiner, a Director since 1984, has been Executive Vice President, General Counsel and Secretary of Inco Limited since August 1993, after having served as Vice President, General Counsel and Secretary of Inco Limited from April 1992 to August 1993. From January 1984 until April 1992, Mr. Feiner was President of Inco Venture Capital Management, the venture capital unit of Inco Limited. Mr. Feiner serves on the Boards of Directors of certain private companies funded by Inco Venture Capital Management.
Mark Skaletsky	54	Mark Skaletsky, a Director since March 2000, has served as the Chairman of the Board and Chief Executive Officer of Essential Therapeutics, Inc. since October 25, 2001. Essential Therapeutics, Inc. is the company formed by the merger of The Althexis Company and Microcide Pharmaceuticals, Inc. Prior to Essential Therapeutics, Mr. Skaletsky served as Chairman of the Board and Chief Executive Officer of The Althexis Company beginning in March 2000. Prior to his positions with The Althexis Company, Mr. Skaletsky served as President, Chief Executive Officer, and a Director of GelTex Pharmaceuticals, Inc. from 1993 until its acquisition by Genzyme Corporation in 2000. From 1988 to 1993, he was Chairman and Chief Executive Officer of Enzytech, Inc., a biotechnology company, and from 1983 to 1988 he was President and

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

Chief Operating Officer of Biogen, Inc., also a biotechnology company.
He is a Director of Isis Pharmaceuticals, Inc.

Committees of the Board of Directors and Meetings

Audit Committee. David W. Carter, Stuart F. Feiner, and Mark Skaletsky currently serve on the Company's Audit Committee. The Audit Committee reviews the engagement of the Company's independent accountants, reviews quarterly and annual financial statements, considers matters relating to accounting policies and internal controls and reviews the scope of annual audits.

Compensation Committee. David W. Carter, Michael R. Eisenson, Stuart F. Feiner, and Mark Skaletsky currently serve on the Compensation Committee. The Compensation Committee reviews, approves and makes recommendations concerning the Company's compensation policies, practices and procedures to ensure that the legal and fiduciary responsibilities of the Board are carried out and that such policies, practices and procedures contribute to the success of the Company. The Compensation Committee also administers the Company's Restated Stock Option Plan and the 2001 Non-Employee Director Stock Plan.

Nominating Committee. On September 24, 2002 the Board voted to establish a Nominating Committee. The Board has not yet created and approved a charter to define the specific duties and responsibilities of the Nominating Committee. The Board has appointed David W. Carter, Stuart F. Feiner, and Mark Skaletsky to serve on this newly created Nominating Committee. The Nominating Committee considers and recommends qualified nominees to the Board of Directors. Since the Nominating

6

Committee was formed in fiscal year 2003 the Committee held no meetings in the fiscal year ended June 30, 2002.

Meeting Attendance. During the fiscal year ended June 30, 2002, there were five meetings of the Board, four meetings of the Audit Committee and three meetings of the Compensation Committee. Further, from time to time, the members of the Board and its Committees acted by unanimous written consent or actions by the Directors without a meeting pursuant to Massachusetts law. Messrs. Sayare, Carter, and Dr. Blättler attended all meetings of the Board. Messrs. Eisenson, Feiner and Skaletsky attended four meetings of the Board. Messrs. Carter and Eisenson attended all the meetings of the Compensation Committee. Messrs. Feiner and Skaletsky attended two meetings of the Compensation Committee. Mr. Feiner, Chairman of the Audit Committee, attended all the meetings of the Audit Committee. Mr. Skaletsky attended two meetings of the Audit Committee and Mr. Carter attended one meeting of the Audit Committee.

Compensation Committee Interlocks and Insider Participation. The Compensation Committee members during fiscal year 2002 were Messrs. David W. Carter, Michael R. Eisenson (Chairman), Stuart F. Feiner, and Mark Skaletsky. None of these Directors is or has been an officer or employee of the Company. Mr. Sayare, though not a member of the Committee, assists the Committee in determining any compensation to be awarded to executive officers other than him. Mr. Sayare provides supplemental information regarding performance evaluations of executive officers other than himself.

Lead Director. In September 2002, the Board of Directors approved the appointment of David W. Carter to serve as Lead Director. The Lead Director's principal duties will include: chairing, and communicating to the Chief Executive Officer the results of, executive Board sessions; interfacing, on behalf of the outside Directors, with management on the evaluation of strategic and other issues; communicating with non-employee directors regarding management plans and initiatives; and such other duties as the Board may from time to time determine.

Compensation of Directors

Non-employee Directors are entitled to receive cash compensation of \$1,500 per Board meeting attended at the Company's offices, and a quarterly retainer of \$3,000. In September 2002, the Board of Directors recommended and approved the position of Lead Director and approved annual cash compensation of \$30,000 to be paid to the Lead Director. Under the provisions of the Company's 2001 Non-Employee Director Stock Plan ("2001 Plan"), that was approved by the stockholders of the Company at the Annual Meeting of Shareholders held November 13, 2001, the non-employee Directors may elect to receive their compensation in the form of cash, shares of common stock and/or stock units. Directors are also reimbursed for travel expenses incurred with respect to attending Board meetings. No additional compensation is paid for attendance at, or activities related to, Audit, Nominating or Compensation Committee meetings.

Under the Company's Restated Stock Option Plan, each non-employee Director, upon first being elected or appointed to the Board after July 9, 1992, and on every fourth anniversary thereof assuming he remains a non-employee Director, receives options to purchase 10,000 shares of Common Stock. Further, the Board may also vote, at its discretion, to issue additional options as deemed appropriate. In that regard, the Board voted to grant options to purchase 25,000 and 50,000 shares of Common Stock to each non-employee Director in December 1997 and July 1998, respectively. In July 1998, the Board also voted to grant options to purchase 50,000 shares of stock to any new non-employee

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

Director, if and when elected to the Board. All options granted under the Plan have ten year terms and exercise prices which are equal to the fair market value of the Common Stock on the date of grant.

7

Summary Director Compensation Table

Name	Year	Annual Compensation (1)		
		Cash	Shares of Common Stock	Stock Units
David W. Carter	2002	\$ 16,500		451.9435
Michael R. Eisenson	2002	\$ 15,016(2)	451(3)	
Stuart F. Feiner	2002	\$ 15,000		451.9435
Mark B. Skaletsky	2002	\$ 16,516	451	

(1) Includes fees for one Board meeting held in fiscal year 2001 that was paid in fiscal year 2002. Excludes payment for one Board meeting held in fiscal year 2002 that was paid in fiscal year 2003.

(2) Pursuant to an agreement between Mr. Eisenson and Harvard Management Co., Inc., all of the cash fees to which Mr. Eisenson is entitled for his performance as a non-employee Director are paid to Harvard Management Co., Inc.

(3) Pursuant to an arrangement between Mr. Eisenson and Aeneas Venture Corporation, Mr. Eisenson has relinquished his right to receive any awards under the 2001 Plan and Aeneas Venture Corporation has agreed to accept any awards made under the 2001 Plan that are made on the basis of Mr. Eisenson's service as a non-employee Director.

Current Executive Officers

The names of and certain other information as of the date hereof regarding each current executive officer of the Company who is not also a member of the Board is set forth below. Executive officers serve at the pleasure of the Board.

Name of Executive Officer	Age	Principal Occupations During the Last Five Years
Gregg D. Beloff	34	Gregg D. Beloff, Vice President, Finance and Chief Financial Officer, joined the Company in March 2001. From 1998 to 2001 he was employed at Adams Harkness & Hill, Inc., most recently as a Vice President in Investment Banking. From 1993 to 1996, Mr. Beloff was employed as an attorney at the law firm of Gaffin & Krattenmaker, P.C. Mr. Beloff holds a Juris Doctorate from the University of Pittsburgh and a Masters of Business Administration from Carnegie Mellon University.
Pauline Jen Ryan	35	Pauline Jen Ryan, Vice President, Business Development since 2000 and Senior Director, Business Development from 1999 to 2000, rejoined the Company in May of 1999. From 1998 to 1999, Ms. Ryan was a Vice President of Capital Management Consulting, Inc., a biomedical consulting firm. From 1994 to 1997, she was Director of Business Development of Organogenesis, Inc., a biotechnology company. Ms. Ryan holds a Masters of Business Administration from Northwestern University's Kellogg School of Management.

8

John M. Lambert, Ph.D.	51	John M. Lambert, Ph.D., Senior Vice President, Pharmaceutical Development, joined the Company in 1987. Dr. Lambert served as the Company's Senior Director of Research from October 1994 to
------------------------	----	---

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

November 1996. Prior to joining ImmunoGen, Dr. Lambert was Assistant Professor of Pathology at the Dana-Farber Cancer Institute, where he worked on the research program supported by ImmunoGen. Dr. Lambert received his Ph.D. in Biochemistry from Cambridge University in England.

Virginia A. Lavery 38 Virginia A. Lavery, Senior Corporate Controller and Treasurer, joined the Company in December 2000. During 2000, Ms. Lavery was self-employed as a financial consultant. From 1999 to 2000, Ms. Lavery was interim Chief Financial Officer of Dynamics Research Corporation, a publicly traded government contractor, after having served as Corporate Controller since 1998. From 1989 to 1998, Ms. Lavery was a Certified Public Accountant with Arthur Andersen, LLP. Ms. Lavery holds a Masters of Science in Public Accounting/Masters of Business Administration from Northeastern University's Graduate School of Professional Accounting.

EXECUTIVE COMPENSATION

The following table (the "Summary Compensation Table") sets forth certain information regarding compensation paid during each of the Company's last three fiscal years to the Company's Chief Executive Officer and to each of the Company's executive officers, other than the Chief Executive Officer, whose total annual salary and bonus exceeded \$100,000 in fiscal year 2002.

9

Summary Compensation Table

Name and Principal Position	Year	Annual Compensation		Long-Term Compensation Awards	All Other Compensation (\$)(3)
		Salary (\$)(1)	Bonus (2)	Securities Underlying Options (#)	
Mitchel Sayare, Ph.D.	2002	366,115		150,000	4,963
Chairman of the Board,	2001	360,000	130,000	165,500	3,428
Chief Executive Officer and President	2000	330,000		85,000	2,696
Walter A. Blättler, Ph.D.	2002	268,250		135,000	3,585
Director and Executive Vice President,	2001	260,000	80,000	150,000	3,040
Science and Technology	2000	250,000		80,000	2,625
Gregg D. Beloff (4)	2002	178,722	26,250	60,000	1,555
Chief Financial Officer and	2001	53,846		75,000	139
Vice President, Finance					
John M. Lambert, Ph.D.	2002	210,000		80,000	3,509
Senior Vice President,	2001	210,000	50,000	94,500	3,039
Pharmaceutical Development	2000	182,000		54,000	2,400
Pauline Jen Ryan.	2002	184,846		65,000	2,503
Vice President,	2001	180,000	40,000	67,500	2,497
Business Development	2000	140,308		25,000	2,014
Virginia A. Lavery (5)	2002	133,269		22,000	2,080
Senior Corporate Controller and Treasurer	2001	63,692	7,200	30,000	24,584

(1) Includes amounts, if any, deferred by each individual under the ImmunoGen, Inc. 401(k) Plan and Trust (the "401(k) Plan").

(2) In June 2002, the Board of Directors approved the following annual bonuses to be paid in July 2002: \$170,000 to Mr. Sayare, \$115,000 to Dr. Blättler, \$73,518 to Dr. Lambert, \$31,114 to Mr. Beloff, \$62,063 to Ms. Ryan and \$36,960 to Ms. Lavery These

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

bonuses are excluded from this table as they were paid during the Company's fiscal year 2003.

(3)

Fiscal year 2002 amounts include term life insurance premiums of \$1,856 for Mr. Sayare, \$1,302 for Dr. Blättler, \$1,021 for Dr. Lambert, \$317 for Ms. Ryan, \$278 for Mr. Beloff and \$228 for Ms. Lavery. Also included are matching contributions under the 401(k) Plan of \$3,107 for Mr. Sayare, \$2,283 for Dr. Blättler, \$2,488 for Dr. Lambert, \$2,186 for Ms. Ryan, \$1,277 for Mr. Beloff and \$1,852 for Ms. Lavery. Fiscal year 2001 amounts include \$24,345 of fees paid to Ms. Lavery for financial consulting services provided to the Company before she became an employee of the Company.

(4)

Mr. Beloff became Chief Financial Officer and Vice President, Finance of the Company in March 2001.

(5)

Ms. Lavery became Senior Corporate Controller of the Company in December 2000.

10

OPTION GRANTS IN LAST FISCAL YEAR

The following table sets forth information regarding each stock option granted during fiscal year 2002 to each individual named in the Summary Compensation Table.

Name	Number of Securities Underlying Options Granted (#)(1)	Percentage of Total Options Granted to Employees in Fiscal Year (%)	Exercise Price (\$)(2)	Expiration Date	Potential Realizable Value at Assumed Annual Rates of Stock Price Appreciation for Option Term (3)	
					5% (\$)	10% (\$)
Mitchel Sayare, Ph.D.	150,000	21.9	3.95	6/5/12	372,620	944,292
Walter A. Blättler, Ph.D.	135,000	19.7	3.95	6/5/12	335,358	849,863
John M. Lambert, Ph.D.	80,000	11.7	3.95	6/5/12	198,731	503,623
Gregg D. Beloff	60,000	8.8	3.95	6/5/12	149,048	377,717
Pauline Jen Ryan	65,000	9.5	3.95	6/5/12	161,469	409,193
Virginia A. Lavery	22,000	3.2	3.95	6/5/12	54,651	138,496

(1)

All options were granted on June 5, 2002 and vest ratably over three years beginning on the date of grant. Under certain circumstances, vesting of options may be accelerated and options may become fully exercisable.

(2)

The exercise price was equal to the fair market value of the Common Stock on the date of grant.

(3)

Amounts represent hypothetical gains that could be achieved for the respective options if exercised at the end of the option term. These gains are based on assumed rates of stock price appreciation of 5% and 10% compounded annually from the date the respective options were granted to their expiration date. The gains shown are net of the option exercise price, but do not include deductions for taxes or other expenses associated with the exercise. Actual gains, if any, on stock option exercises will depend on the future performance of the Common Stock, the optionee's continued employment through the option period and the date on which the options are exercised. These rates of appreciation are mandated by the rules of the Securities and Exchange Commission (the "Commission") and do not represent the Company's estimate or projection of future Common Stock prices.

AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

The following table provides information as to each individual named in the Summary Compensation Table regarding the exercise of options during the 2002 fiscal year. In addition, this table includes the number of shares covered by both exercisable and unexercisable options as of June 30, 2002 and the value

11

of "in the money" options, which values represent the positive spread between the exercise price of any such option and the fiscal year-end value of the Common Stock.

Name	Shares Acquired on Exercise (#)	Value Realized (\$)	Number of Securities Underlying Unexercised Options at Fiscal Year-End (#)		Value of Unexercised In-The-Money Options at Fiscal Year-End \$(1)	
			Exercisable	Unexercisable	Exercisable	Unexercisable
Mitchel Sayare, Ph.D.			764,227	289,939	641,665	
Walter A. Blättler, Ph.D.			553,751	261,666	477,370	
Gregg D. Beloff			18,750	116,250		
Pauline Jen Ryan			69,167	128,333	6,660	2,220
John M. Lambert, Ph.D.			360,034	166,333	290,127	
Virginia A. Lavery			7,500	44,500		

(1)

Value is based on the last sale price per share (\$2.69) on June 28, 2002, as reported on the Nasdaq National Market, less the applicable option exercise price. Each option has an exercise price equal to the fair market value of the Common Stock on the date of grant.

EMPLOYMENT CONTRACTS, TERMINATION OF EMPLOYMENT AND CHANGE IN CONTROL AGREEMENTS

The Company entered into employment agreements with Dr. Blättler, Dr. Lambert, Mr. Beloff, Ms. Ryan and Ms. Lavery on their respective hire dates. These agreements currently provide for annual salaries of \$271,000 for Dr. Blättler, \$227,115 for Dr. Lambert, \$191,619 for Mr. Beloff, \$198,218 for Ms. Ryan and \$150,075 for Ms. Lavery. Mr. Beloff's employment agreement provides that he will receive a minimum guaranteed bonus during his first year of employment. These agreements may be terminated by either the Company or the executive officer upon 90 days' prior written notice. In addition, each agreement provides that the Company may terminate the employment of the executive officer at any time for cause (as defined in the respective agreements). The agreements with Dr. Blättler and Dr. Lambert also provide that these executive officers will not engage in any business competitive with the business of the Company for a period of two years following termination of employment.

In making determinations of salary and benefits to be provided under these employment agreements, the Compensation Committee of the Board of Directors took into consideration, in addition to contractual commitments, Company personnel policies.

Contractual language is included in stock option agreements between the Company and members of its senior management group to the effect that all unvested options of the affected employee will become immediately exercisable in instances where:

(i)

(A) a person becomes the beneficial owner of fifty percent or more of the voting securities of the Company, or

(B)

the Board approves a consolidation or merger of the Company whereby the shareholders of the Company would not retain fifty percent or more of the voting securities of the Company after the consolidation or merger, and

(ii)

(A) a material change is made in the Restated Stock Option Plan or an option granted thereunder (except as provided in Section 16(b) of the Plan), or

(B)

the affected employee is, within two years, terminated for any reason other than for cause.

12

STOCK PRICE PERFORMANCE GRAPH

The graph and table below compare the annual percentage change in the Company's cumulative total stockholder return on its Common Stock for the period from June 30, 1997 through June 30, 2002 (as measured by dividing (i) the sum of (A) the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and (B) the difference between the Company's share price at the end and the beginning of the measurement period; by (ii) the share price at the beginning of the measurement period) with the total cumulative return of the Nasdaq Stock Market Index (U.S.) and the Nasdaq Pharmaceutical Stocks Total Return Index during such period. The Company has not paid any dividends on the Common Stock, and no dividends are included in the representation of the Company's performance. The stock price performance on the graph below is not necessarily indicative of future price performance. This graph is not "soliciting material," is not deemed filed with the Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934 whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. Information used on the graph for the Nasdaq Pharmaceutical Stocks Total Return Index and the Nasdaq Stock Market Index (U.S.) was prepared by the Center for Research in Security Prices, a source believed to be reliable, but the Company is not responsible for any errors or omissions in such information.

	1997	1998	1999	2000	2001	2002
IMMUNOGEN, INC.	\$ 100.00	\$ 112.00	\$ 148.00	\$ 772.00	\$ 1,280.00	\$ 172.16
NASDAQ STOCK MARKET INDEX (U.S.)	\$ 100.00	\$ 131.63	\$ 189.11	\$ 279.59	\$ 151.56	\$ 103.27
NASDAQ PHARMACEUTICAL	\$ 100.00	\$ 102.19	\$ 143.36	\$ 329.21	\$ 277.13	\$ 162.84

The above graph and table assume \$100 invested on June 30, 1997 with all dividends reinvested, in each of the Common Stock, the Nasdaq Stock Market Index (U.S.) and the Nasdaq Pharmaceutical Stocks Total Return Index. Upon written request by any shareholder, the Company will promptly provide a list of the companies comprising the Nasdaq Pharmaceutical Stocks Total Return Index.

13

COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION*

The Compensation Committee of the Board is comprised entirely of non-employee Directors. The Compensation Committee determines the base salaries of the Company's executive officers and the amount of annual bonus awards, if any, to be paid to the executive officers. In addition, the Compensation Committee administers the Company's Restated Stock Option Plan, as amended (the "Plan"), under which stock options may be granted to executive officers and other employees of the Company, as well as to non-employee Directors.

Compensation Policy and Components of Compensation

The Compensation Committee's fundamental executive compensation philosophy is to enable the Company to attract and retain key executives, and to motivate those executives to achieve the Company's long-term objective of becoming a profitable company. Attracting and retaining key executives is important to any organization. This challenge is especially difficult in the biotechnology industry where executives are required to remain focused and committed throughout many years of product development and financial instability.

Each executive officer's compensation package is reviewed at least annually and may be comprised of up to three components: base salary, incentive cash bonuses and stock options. In addition, the Company's executive officers are eligible to participate in all employee benefit programs generally available to all other ImmunoGen employees.

Progress toward the Company's broad strategic goal of becoming a profitable biopharmaceutical company is measured by specific corporate objectives and annual milestones. Personal objectives and milestones by which individual executives of the Company are evaluated fit within the framework of the Company's overall goals and objectives. The Compensation Committee considers factors such as changes in business conditions and other relevant external circumstances when evaluating the performance of the individual executives.

*

The report of the Compensation Committee shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates this report by reference.

Base Salaries of Executive Officers

The Compensation Committee sets the salaries of the Company's executive officers by reviewing independently-prepared surveys of biotechnology industry compensation as well as other available information on the base salaries of executive officers in comparable positions in other biotechnology companies. There is substantial overlap between the biotechnology companies whose compensation practices are reflected in such surveys and the biotechnology companies that are included in the Nasdaq Pharmaceutical Stocks Total Return Index (see "Stock Price Performance Graph"). Comparative factors considered include, but are not limited to, company size, stage of development of a company's products, and geographic location. The Compensation Committee uses the collected data as well as the experience of the members of the Compensation Committee in hiring and managing personnel to set salaries. The Compensation Committee also takes into account, for both current and new executive officers, competitive industry factors, breadth of experience, length of service and recent individual performance. It is not the Company's intent to establish fixed levels of compensation in general or for specific positions, but rather to establish compensation on a case-by-case basis as recommended by management and confirmed by the Compensation Committee. The Company's executive officer salaries, as currently paid, are estimated to range from the 48th to 92nd percentile of comparable biotechnology companies. The salary of the Company's Chairman of the Board, President and Chief Executive Officer is estimated to be in the 83rd percentile of such range.

In certain cases initial annual base compensation was established pursuant to employment agreements with executive officers (see "Employment Contracts, Termination of Employment and Change in Control Agreements"). The terms of such employment contracts were reviewed and authorized by the Board (including members of the Committee but excluding any interested officer) and were consistent with the Company's compensation policies then in place.

In October 2001, Dr. Blättler's base salary was set at \$271,000 annually. In July 2002, Dr. Lambert's base salary was set at \$227,115, Mr. Beloff's base salary was set at \$191,619, Ms. Ryan's base salary was set at \$198,218 and Ms. Lavery's base salary was set at \$150,075.

Bonus Awards

The Company does not have formal incentive or bonus plans for executives. In the fiscal year ended June 30, 2002, Mr. Beloff received a bonus of \$26,500, pursuant to his employment agreement. No bonuses were awarded to any other executive officers of the Company during the fiscal year ended June 30, 2002. In June 2002, the Board of Directors approved bonuses for all employees of the Company to be paid in July 2002. The following annual bonuses were awarded to executive officers of the Company to be paid in July 2002: \$115,000 to Dr. Blättler, \$73,518 to Dr. Lambert, \$31,114 to Mr. Beloff, \$62,063 to Ms. Ryan and \$36,960 to Ms. Lavery. In January 2001, the Compensation Committee approved bonuses for all employees of the Company. On January 25, 2001, Dr. Blättler was awarded a bonus of \$80,000, Dr. Lambert was awarded a bonus of \$50,000, Ms. Ryan was awarded a bonus of \$40,000 and Ms. Lavery was awarded a bonus of \$7,200.

Stock Option Plan

Subject to the provisions of the Plan, the Committee has the authority to determine the terms under which options are granted and the individuals to whom such options may be granted. The Committee believes that equity participation is a key component of its executive compensation program. The stock option program is the Company's major long-term incentive plan, designed to retain executive officers and

15

other employees and motivate them to enhance shareholder value by aligning the long-term interests of the Company's employees with those of its shareholders. Stock options provide an effective long-term incentive for all employees to create shareholder value since the full benefit of the options cannot be realized unless an appreciation in the price of the Company's Common Stock occurs. The executive officers participate in the Plan in the same manner as all of the Company's full-time employees. Initial stock option awards for new employees, which are individually determined prior to employment, are derived from the employee's anticipated contribution to the Company's growth and are designed to be competitive with awards granted by other biotechnology companies. Subsequent annual stock option awards are based on historical levels of prior grants, position within the Company and individual performance. For fiscal years 2000, 2001 and 2002, stock options were awarded to all current executive officers in January 2000, January 2001 and June 2002, respectively. All options are issued with exercise prices equal to the fair market value of the Company's Common Stock on the date of grant. The options granted in fiscal years 2000, 2001 and 2002 vest as to one-third of the shares on each anniversary date of the date of grant. Vesting of options may be accelerated and options may become fully exercisable upon the occurrence of certain events such as a change in control of the Company (see "Employment Contracts, Termination of Employment and Change in Control Agreements").

In addition to incentive stock options, the Committee also has discretionary authority under the Plan to grant non-qualified options to certain individuals, including executive officers of the Company. Of the current executive officers, Mr. Sayare, Dr. Blättler, Dr. Lambert, Mr. Beloff, Ms. Ryan and Ms. Lavery have been granted non-qualified options. In each case, the options were granted with exercise prices equal to the fair market value of the Common Stock on the date of grant and vested over three or four years.

Compensation of the Chief Executive Officer

Mr. Sayare's annual base salary has been determined in accordance with the criteria outlined in other sections of this report, the Compensation Committee's evaluation of the Company's overall performance and Mr. Sayare's individual performance. Performance was measured by the achievement of certain goals over the last several years, including the consummation of several significant financing transactions and the continued development of the Company's key technology platforms. Mr. Sayare's salary was increased to \$375,000 on February 1, 2002.

Mr. Sayare was paid a cash bonus of \$130,000 in 2001. No cash bonus was paid to Mr. Sayare during fiscal years 2002 and 2000. In June 2002, the Board of Directors approved a bonus of \$170,000 to be paid to Mr. Sayare in July 2002. In fiscal 2000, Mr. Sayare was awarded options to purchase 85,000 shares of Common Stock. In fiscal 2001, Mr. Sayare was awarded options to purchase 165,000 shares of Common Stock. In fiscal 2002, Mr. Sayare was granted options to purchase 150,000 shares of Common Stock. The options granted to Mr. Sayare in fiscal years 2000, 2001 and 2002 vest as to one-third of the shares each year after issuance beginning one year from the date of grant. All options are subject to Mr. Sayare's continued employment with the Company and were issued with exercise prices equal to the fair market value of the Common Stock on the date of grant.

Certain Agreements

The Company has entered into agreements with certain of its executive officers relating to employment and separation. In making determinations of salary and benefits to be provided under these employment and separation agreements, the Compensation Committee took into consideration contractual commitments and Company policies. (See "Employment Contracts, Termination of Employment and Change in Control Agreements").

Members of the ImmunoGen, Inc. Compensation Committee
David W. Carter
Michael R. Eisenson, Chairman
Stuart F. Feiner
Mark B. Skaletsky

REPORT OF AUDIT COMMITTEE

The Audit Committee, as described on page 6, is comprised of three independent Directors. The role of the Audit Committee is to assist the Board of Directors in its oversight of the Company's accounting and financial reporting principles, policies and procedures as well as the adequacy of the Company's systems of internal accounting control and the quality and integrity of the Company's financial statements. All members of the Committee meet the Nasdaq National Marketplace rules test for independence. The Committee operates pursuant to a charter that was most recently amended by the Board in April 2002 and is attached as Appendix A to this Proxy Statement (as so amended, the "Charter"). As set forth in the charter, management of the Company is responsible for the preparation, presentation and integrity of the Company's financial statements, the Company's accounting and financial reporting principles, and internal accounting controls designed to assure compliance with accounting standards and applicable laws and regulations. The Company's independent auditors are responsible for auditing the Company's financial statements and expressing an opinion as to their conformity with accounting principles generally accepted in the United States.

In assisting the Board in its oversight function, the Committee has considered and discussed the Company's audited financial statements for the year ended June 30, 2002 with management and the Company's independent auditors, Ernst & Young LLP. The Committee has also discussed and reviewed with the independent auditors the matters required to be discussed by the current Statement on Auditing Standards No. 61, "Communication with Audit Committees," as amended. The Committee has also received the written disclosures and the letter from the independent auditors required by the current Independence Standards Board Standard No. 1, "Independence Discussions with Audit Committees" and has discussed with the independent auditors the auditors' independence from the Company and its management. The Audit Committee has also discussed with management and the independent auditors the quality and adequacy of the Company's internal accounting controls. The Audit Committee has reviewed with the independent auditors their audit plan, audit scope and identification of audit risks for the year ended June 30, 2002 and has considered, with a view to maintaining the independence of the Company's independent auditors, the nature and scope of the non-audit services supplied to the Company by its independent auditors.

The members of the Audit Committee are not professionally engaged in the practice of auditing or accounting, are not experts in the fields of accounting or auditing, and are not employed by the Company for accounting or financial management or for any aspects of the Company's systems of internal accounting control. Members of the Committee rely, without independent verification, on the information provided to them, and on the representations made, by management and the Company's independent auditors. Accordingly, the Audit Committee's oversight does not provide an independent basis to determine that management has maintained appropriate accounting and financial reporting principles and policies, or internal accounting controls and procedures, designed to assure compliance with accounting standards and applicable laws and regulations. In addition, the Audit Committee's considerations and discussions referred to above do not assure that the audit of the Company's financial statements has been carried out in accordance with auditing standards generally accepted in the United States or that the Company's financial statements are presented in accordance with accounting policies generally accepted in the United States.

Based upon the reports, discussions and reviews described in this Report, and subject to the limitations on the role and responsibilities of the Committee referred to above and in the Charter of the Audit Committee, the Committee has recommended to the Board of Directors, and the Board of Directors

has approved the Committee's recommendation that the Company's audited financial statements for the year ended June 30, 2002 be included in the Company's Annual Report to Shareholders for the year ended June 30, 2002 and the Company's Annual Report on Form 10-K for the year ended June 30, 2002 be filed with the U.S. Securities and Exchange Commission.

Members of the ImmunoGen, Inc. Audit Committee
Stuart F. Feiner, Chairman
David W. Carter

Mark Skaletsky

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company's Directors and executive officers, and persons holding more than 10% of the Common Stock, to file with the Securities and Exchange Commission (the "SEC") initial reports of ownership and reports of changes in ownership of Common Stock. Executive officers, Directors and greater than 10% shareholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.

To the Company's knowledge, based solely on review of the copies of such reports furnished to it and written representations that no other reports were required, during the fiscal year ended June 30, 2002, the Company's executive officers, Directors and greater than 10% beneficial owners of its Common Stock complied with all applicable Section 16(a) filing requirements, except that a Form 4 report was filed late on behalf of Stuart Feiner (reporting 18 transactions) and a Form 5 was filed late on behalf of each of Mitchel Sayare, Walter Blättler, Gregg D. Beloff, Pauline Jen Ryan, John Lambert and Virginia A. Lavery (each of whom reported two stock option grants). Shire BioChem Inc. was formerly the owner of warrants whose terms of exercise into common stock varied with the market price of the Company's common stock. Prior to Shire BioChem Inc.'s exercise of warrants on July 29, 2002, Shire BioChem Inc. may have been required to file a Form 3 as a result of temporary market conditions giving it the right to acquire beneficial ownership of more than 10% of the Company's outstanding common stock. The Company is not aware of Shire BioChem Inc. making such a filing. At all times since the exercise of the warrants, Shire BioChem Inc. has beneficially owned less than 10% of the Company's outstanding common stock.

CERTAIN TRANSACTIONS

The holder of approximately 533,841 shares of Common Stock (the "Registrable Securities") is entitled to certain rights to register such shares under the Securities Act of 1933, as amended (the "Securities Act"), for sale to the public pursuant to a Registration Rights Agreement by and among the Company and the holders of Registrable Securities, as amended (the "Registration Rights Agreement"). The holder of Registrable Securities is Aeneas Venture Corporation ("Aeneas"). Michael R. Eisenson, a Director of the Company, is President and Chief Executive Officer of Charlesbank Capital Partners, LLC, the successor to Harvard Private Capital Group, Inc. and the investment advisor to Aeneas. Aeneas has the right to require the Company, on not more than two occasions, whether or not the Company proposes to register any of its Common Stock for sale, to register all or part of their shares for sale to the public under the Securities Act, subject to certain conditions and limitations. In addition, Aeneas may require the Company to register all or part of its shares on Form S-3 (or a successor short form of registration) if the Company then qualifies for use of such form, subject to certain conditions and limitations.

18

INDEPENDENT AUDITORS

Ernst & Young LLP, independent accountants, audited the Company's financial statements for the fiscal year ended June 30, 2002. The Company expects that representatives of Ernst & Young LLP will be present at the Meeting, with the opportunity to make a statement if they so desire, and will be available to respond to appropriate questions.

Audit Fees

The Company and Ernst & Young LLP negotiated fees of \$101,500 for their audit of the Company's annual financial statements for the fiscal year ended June 30, 2002 and for their review of the Company's Quarterly Reports on Form 10-Q filed during the last fiscal year. During the year ended June 30, 2002, the Company paid Ernst & Young LLP \$48,160 of these fees. The Company also paid Ernst & Young \$6,000 related to consultation on several other accounting matters.

During the Company's fiscal year ended June 30, 2002, the Company paid Ernst & Young LLP a total of \$34,760 for their preparation and review of the Company's federal and state tax returns and consultation on various tax matters.

Financial Information Systems Design and Implementation Fees

During the Company's fiscal year ended June 30, 2002, the Company did not pay Ernst & Young LLP any fees for financial information systems design and implementation.

All Other Fees

During the Company's fiscal year ended June 30, 2002, the Company did not pay Ernst & Young LLP any other fees.

ELECTION OF DIRECTORS
(Notice Item 1)

Under the Company's By-Laws, the number of Directors is fixed from time to time by the shareholders, and Directors serve in office until the next Annual Meeting and until their successors have been elected and qualified. At the Meeting the number of Directors will be fixed at six and six Directors will be elected.

The enclosed Proxy, unless authority to vote is withheld, will be voted for the election of the nominees named herein as Directors of the Company. The nominees are Mitchel Sayare, Ph.D., Walter A. Blättler, Ph.D., David W. Carter, Michael R. Eisenson, Stuart F. Feiner, and Mark Skaletsky. The Board has no reason to believe that any nominee will become unavailable. However, in the event that any one or more of such nominees shall unexpectedly become unavailable for election, votes will be cast, pursuant to authority granted by the enclosed Proxy, for such person or persons as may be designated by the Board.

A plurality of the votes cast at the Meeting is required to elect each nominee as a Director.

THE BOARD OF DIRECTORS RECOMMENDS THAT THE NUMBER OF DIRECTORS BE FIXED AT SIX AND RECOMMENDS THE ELECTION OF THE NOMINEES AS DIRECTORS.

**SHAREHOLDER PROPOSAL: AMENDMENT OF THE COMPANY'S ARTICLES OF
ORGANIZATION TO DECREASE FROM 75,000,000 SHARES TO 50,000,000 SHARES
THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK
AUTHORIZED TO BE ISSUED BY THE COMPANY**

(Notice Item 2)

An ImmunoGen shareholder has informed management of his intention to present the following resolution set forth below for consideration at the Annual Meeting. The name, address and number of shares held by such shareholder will be promptly furnished to any shareholder upon oral or written request to Jonathan L. Kravetz, Esq., Clerk of the Company, who may be contacted at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., One Financial Center, Boston, Massachusetts 02111 by mail or by calling (617) 542-6000.

A private investor, and shareholder of ImmunoGen, Inc. proposes that "the number of shares currently authorized is not in the best interest of the existing Shareholders of the Company, and that the Shareholders adopt an amendment of the Company's Articles of Organization effecting the proposed decrease.

Given the current (June 2002) depressed share value of ImmunoGen common stock, it is self evident that the increased share authorization, approved by the Shareholders in the annual meeting held November 13, 2001, is no longer an effective method to achieve the aims originally stated as the rationale for the increase (such as possible acquisitions and future financing). In fact it is also clear that continued increased share issuance by the Company would be counterproductive to the interests of the existing Shareholders, resulting in further dilution of earnings per share, reduction of book value per share and most importantly diminishing voting power.

Until the management of ImmunoGen has clearly defined the Company's objectives in the future regarding means and terms of use of the Company's Common Stock, it would be wise of the current shareholders to reduce the number available for issuance.

RESOLVED: That the Company's Articles of Organization be amended to decrease the aggregate number of shares of common stock authorized to be issued by the Company from 75,000,000 to 50,000,000 shares."

THE BOARD OF DIRECTORS AND MANAGEMENT OPPOSE THE FOREGOING PROPOSAL AND RECOMMEND A VOTE AGAINST IT FOR THE FOLLOWING REASONS:

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

As stated below the Board of Directors believes that it is advisable and necessary to maintain the Company's authorized Common Stock at 75,000,000 shares.

At the annual meeting held on November 13, 2001, a vote was taken to amend the Company's Articles of Organization to increase the aggregate number of shares of common stock authorized to be issued by the Company from 50,000,000 to 75,000,000 shares. An overwhelming majority of 96% of the shares present and voted at the meeting voted in favor of the resolution.

The Board of Directors believes that this shareholder support reflects the shared view that it is in the best interest of the Company to have sufficient additional authorized but unissued shares of Common Stock available in order to provide flexibility for corporate action in the future. The Board of Directors believes that there is a continuing need to have these additional authorized but unissued shares of Common Stock available. Management believes that the availability of additional authorized shares for issuance from time to time in the Board of Directors' discretion in connection with possible acquisitions of other companies, acquisitions of technology, future financings, investment opportunities, collaborator investments, stock splits or dividends, stock option grants, or for other corporate purposes is desirable in order to avoid repeated separate amendments to the Company's Articles of Organization and the delay and expense incurred in holding special meetings of the shareholders to approve such amendments. There are at present no specific understandings, arrangements or agreements with respect to any future acquisitions that would require the Company to issue a material amount of new shares of its Common Stock. The Board of Directors believes that the currently available unissued shares provide sufficient flexibility for corporate action in the future.

As of September 13, 2002, 43,878,488 shares of Common Stock were issued and outstanding (excluding treasury shares) and approximately 7,166,267 shares of Common Stock were reserved for issuance upon the conversion of existing securities and exercise of rights granted under the Company's Restated Stock Option Plan and 2001 Non-Employee Director Stock Plan. In the event that this stockholder proposal were to pass and the shares of common stock authorized to be issued by the Company reduced from 75,000,000 to 50,000,000 shares, the Company will have a deficit of 1,044,755 shares necessary to satisfy its existing legal obligations. Conversely, with 75,000,000 authorized shares of Common Stock, a total of approximately 23,955,245 shares of Common Stock are available for future issuance.

No further authorization by vote of the shareholders will be solicited for the issuance of the additional shares of Common Stock that are authorized, except as might be required by law, regulatory authorities or rules of the Nasdaq National Market or any other stock exchange on which the Company's shares may then be listed. The issuance of additional shares of Common Stock could have the effect of diluting existing shareholder earnings per share, book value per share and voting power. The shareholders of the Company do not have any preemptive right to purchase or subscribe for any part of any new or additional issuance of the Company's securities.

For the reasons stated above, the Board of Directors and management believe that the shareholder proposal is not in the best interest of the Corporation and its shareholders.

ACCORDINGLY, THE BOARD OF DIRECTORS AND MANAGEMENT RECOMMEND A VOTE AGAINST THIS SHAREHOLDER PROPOSAL.

21

SHAREHOLDER PROPOSALS AND OTHER MATTERS

In order to be considered for inclusion in the proxy statement distributed to shareholders prior to the Company's annual meeting in 2003, the Company must receive a shareholder proposal no later than June 14, 2003. Proposals should be delivered in writing to ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139. One or more shareholders who hold at least a one-tenth part in interest of the capital stock entitled to vote at the meeting and who do not wish to include their proposal in such proxy statement but who wish to present a proposal at the Company's annual meeting of shareholders in 2003, must notify the Company in writing at the above-referenced address no later than October 23, 2003. All other shareholders who wish to present a proposal at such annual meeting must notify the Company in writing at the above-referenced address no later than August 23, 2003 in order for their proposal to be considered timely for purposes of Rule 14a-4 under the Securities Exchange Act of 1934, as amended. Pursuant to Rule 14a-4, management proxies may confer discretionary authority to vote on any matters presented by a shareholder at the Meeting if the proposals are received by the Company after August 23, 2003.

The Board does not know of any other matters that will be brought before the Meeting. If other business is properly presented for consideration at the Meeting, it is intended that the shares represented by the enclosed Proxy will be voted in accordance with the judgment of Mitchel Sayare, Ph.D. and Walter A. Blättler, Ph.D. or either of them, acting as proxies, on such matters.

In order that your shares may be represented if you do not plan to attend the Meeting, and in order to assure the required quorum, please complete, sign, date and return your Proxy promptly.

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

The Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2002 (other than exhibits attached thereto) filed by the Company with the Commission, which provides additional information about the Company, is available to beneficial owners of the Company's Common Stock without charge upon written or oral request to the Company's Investor Relations Department at 128 Sidney Street, Cambridge, Massachusetts 02139 (tel: 617-995-2500).

By order of the Board of Directors

JONATHAN L. KRAVETZ,
ESQ.
Clerk

October 11, 2002

22

APPENDIX A

IMMUNOGEN, INC. **Charter of the Audit Committee of the Board of Directors, as Amended***

I. Purpose of the Audit Committee

The purpose of the Audit Committee is to provide assistance to the Board of Directors (the "Board") of ImmunoGen, Inc. (the "Company") in fulfilling its oversight responsibilities relating to (i) corporate accounting principles, policies and procedures, (ii) financial reporting practices and procedures, (iii) the adequacy of the systems of internal accounting control, and (iv) the quality and integrity of the financial information and reports of the Company. To accomplish this purpose, the Audit Committee's primary duties and responsibilities are to:

1. assist the Board in overseeing the Company's accounting and financial reporting principles, policies and procedures and internal accounting controls and procedures, all of which are designed to assure compliance with accounting standards and applicable laws and regulations;
2. assist the Board in overseeing the integrity of the Company's policies, procedures, practices and systems covering the security of Company information stored, maintained and transmitted electronically or by or through any electronic device and any significant breaches in such policies, procedures, practices and systems.
3. assist the Board in overseeing the Company's financial statements and the independent audit thereof;
4. assist the Board in selecting the outside auditors to be retained (or nominate the outside auditors to be proposed for shareholder approval in any proxy statement), evaluate and, when deemed appropriate, report to the Board for their approval the replacement of the outside auditors; and
5. evaluate the independence of the outside auditors.

The function of the Audit Committee is oversight. In fulfilling its role, it is recognized that the members of the Audit Committee are not full-time employees of the Company and are not, and do not represent themselves to be, accountants or auditors by profession or experts in the

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

fields of accounting or auditing, including, but not limited to, in respect of the independence of independent auditors. As such, it is not the duty or the responsibility of the Audit Committee or any of its members to conduct any type of audit or accounting review or procedure or set auditor independence standards. Each member of the Audit Committee shall be entitled to reasonably rely on (i) the integrity of those persons and organizations within and outside the Company from whom it receives information, (ii) the accuracy of the financial and other information provided to the Audit Committee by such persons or organizations absent actual knowledge to the contrary (in which event such occurrence shall be promptly reported to the Board) and (iii) representations made by the management of the Company as to any information technology, internal audit and other non-audit services provided by the outside auditors of the Company.

* Last amended as of April 29, 2002.

A-1

The management of the Company is responsible for the preparation, presentation and integrity of the Company's financial statements. Management is also responsible for establishing and maintaining the appropriate accounting and financial reporting principles and policies and internal controls and procedures designed to assure compliance with accounting and independence standards and all applicable laws and regulations. The outside auditors are responsible for planning and carrying out a proper audit and reviews, including reviews of the Company's quarterly financial statements prior to the filing of each quarterly report on Form 10-Q with regulatory bodies and stock exchanges or similar bodies and other procedures and in connection with the Company's annual financial statements.

The outside auditors for the Company are ultimately accountable to the Board and to the Audit Committee.

II. Composition of the Audit Committee

The Audit Committee shall be comprised of at least three Directors, as determined by the Board. Each member must be independent of the Company and its subsidiaries; that is, no member of the Audit Committee may be an officer or employee of the Company or its subsidiaries, and each member shall be free of any relationship with the Company or its subsidiaries which, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a Director. In addition, each member must otherwise satisfy the applicable independence and financial and other requisite expertise requirements under the applicable rules of the National Association of Securities Dealers, Inc. or any other applicable securities exchange or other regulatory body.

The members of the Audit Committee shall be elected by the Board annually. The Chairperson shall be selected by the Board from among its members, and either the Board or the Chairperson shall periodically review the performance of each member of the Audit Committee to assess his or her effectiveness as an Audit Committee member.

III. Meetings of the Audit Committee

The Audit Committee shall meet at least four times annually, or more frequently as circumstances dictate, to meet its oversight responsibility, including discussing with management the annual audited financial statements, the quarterly financial statements or any other matters which the Audit Committee deems necessary to carry out its duties and responsibilities. The Audit Committee may request any officer or employee of the Company or the Company's outside counsel or outside auditors to attend a meeting of the Audit Committee or to meet with any members of, or consultants to, the Audit Committee. In addition, as part of its job to foster open communication, the Audit Committee should meet at least annually with management and the outside auditors separately to discuss any matters that the Audit Committee or any of these groups believe should be discussed privately.

Members of the Audit Committee may participate in a meeting of the Audit Committee by means of a conference call or other communications equipment by means of which all persons participating in the meeting can hear each other.

A-2

IV. Duties and Powers of the Audit Committee

To carry out its purposes, the Audit Committee shall have the following duties and powers:

1.

With respect to the outside auditors

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

- (a) to review the performance of the outside auditors and to make recommendations to the Board regarding the appointment or termination of the outside auditors;
- (b) to review the nature and scope of all audit and non-audit services of the outside auditors and the fees charged by the outside auditors for audit and non-audit services;
- (c) to ensure that the outside auditors prepare and deliver annually a formal, written statement (the "Statement") delineating all relationships between such auditors and the Company consistent with Independence Standards Board Standard No. 1 (it being understood that the outside auditors are responsible for the accuracy and completeness of this Statement), addressing at least the matters set forth in such Standard No. 1 and any non-audit services provided to the Company and any similar standards or other requirements applicable to such auditors;
- (d) to review and discuss with the outside auditors any relationships or services disclosed in the Statement that may impact the objectivity and independence of the outside auditors and to recommend that the Board take appropriate action in response to this Statement to satisfy itself of the outside auditors' independence and objectivity; in connection herewith, the outside auditors shall also submit to the Company annually a formal written statement of the fees billed for each of the following categories of services rendered by the outside auditors: (a) the audit of the Company's annual financial statements for the most recent fiscal year and the reviews of the financial statements included in the Company's quarterly reports on Form 10-Q for that fiscal year; (b) information technology consulting services for the most recent fiscal year, in the aggregate and by each service, separately identifying fees for such services relating to financial information systems design and implementation; and (c) all other services rendered by the outside auditors for the most recent fiscal year, in the aggregate and by each service; the Committee shall, if applicable, also consider whether the outside auditors' provision of the services referred to in (b) and/or (c) above or other non-audit services to the Company is compatible with maintaining the independence of the outside auditors; and
- (e) to instruct the outside auditors that the outside auditors are ultimately accountable to the Board and the Audit Committee.

2.

With respect to documents/reports review

- (a) to review and assess, at least annually, the adequacy of this Charter, and to make recommendations to the Board, as conditions dictate, to amend or update this Charter;
- (b) to review with management and the outside auditors the Company's annual financial statements, including a discussion with the outside auditors of the matters required to be discussed by Statement of Auditing Standards No. 61, *Communication With Audit Committees* ("SAS No. 61"), and any similar standards or other requirements applicable to such auditors; and

A-3

- (c) to require the outside auditors to conduct an interim financial review, in accordance with Statement of Auditing Standards No. 71, *Interim Financial Information*, prior to filing by the Company of its quarterly report on Form 10-Q, and to discuss with the outside auditors, when needed as determined by SAS No. 61, matters relevant to the Form 10-Q prior to the Company's filing of such document or prior to the release of earnings. The Chairperson of the Audit Committee, or any individual member selected by the Audit Committee, may represent the entire Audit Committee for purposes of this paragraph.

3.

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

With respect to the financial reporting process and internal accounting controls and procedures

- (a) to advise management and the outside auditors that they are expected to provide to the Audit Committee a timely analysis of significant financial reporting issues and practices;
- (b) to consider any reports or communications (and management's responses thereto) submitted to the Audit Committee by the outside auditors required by or referred to in SAS 61, as may be modified or supplemented;
- (c) to review, in consultation with management and the outside auditors, the integrity of the Company's financial reporting processes, both internal and external;
- (d) to review, in consultation with management and the outside auditors, the integrity of the Company's information security policies, procedures and processes, both internal and external;
- (e) to establish a regular system of reporting to the Audit Committee by management and the outside auditors regarding any significant judgments made in management's preparation of the financial statements and any significant difficulties encountered during the course of the review or audit, including any restrictions on the scope of work or access to required information;
- (f) to review any significant disagreement between management and the outside auditors in connection with the preparation of the financial statements;
- (g) during its regularly scheduled meetings, to meet separately with the outside auditors;
- (h) prior to the commencement thereof, to review the planned scope of the annual examination to be undertaken by the outside auditors as well as the results of such examination and the recommendations of the outside auditors;
- (i) prior to presentation to the Board, to review the annual financial statements (including the notes thereto) and the outside auditors' opinion to be included in the Company's Annual Report to Shareholders, Annual Report on Form 10-K and any other filings with regulatory bodies or stock exchanges; and
- (j) to obtain the outside auditors' assurance that the audit was conducted in a manner consistent with Section 10A of the Securities Exchange Act of 1934, as amended, and all applicable rules and regulations thereunder, which sets forth certain procedures to be followed in any audit of financial statements required under such rules and regulations.

A-4

4.

With respect to legal compliance/general

- (a) to review, with the Company's counsel, any legal matter that could have a significant impact on the Company's financial statements;
- (b) to report through the Chairperson or other Audit Committee member to the Board following meetings of the Audit Committee; and
- (c)

Edgar Filing: IMMUNOGEN INC - Form DEF 14A

to maintain minutes or other records of meetings and activities of the Audit Committee.

V. Resources and Authority of the Audit Committee

The Audit Committee shall have the resources and authority appropriate to fully discharge its functions, duties and responsibilities, including the authority to engage outside auditors for special audits, reviews and other procedures and to retain special counsel and other experts or consultants.

A-5

PROXY

**IMMUNOGEN, INC.
PROXY SOLICITED BY THE BOARD OF DIRECTORS
OF IMMUNOGEN, INC. FOR THE
ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON NOVEMBER 12, 2002**

PROXY

The undersigned hereby acknowledges receipt of the Notice of Annual Meeting of Shareholders and Proxy Statement dated October 11, 2002, and does hereby appoint Mitchel Sayare, Ph.D. and Walter A. Blättler, Ph.D. ("the proxies") or either of them, the undersigned's attorneys-in-fact and proxies, with full power of substitution in each, for and in the name of the undersigned, with all the powers the undersigned would possess if personally present, hereby revoking any proxy heretofore given, to appear and represent and vote all shares of Common Stock of ImmunoGen, Inc. which the undersigned would be entitled to vote if personally present at the Annual Meeting of Shareholders to be held at the offices of the Company, 128 Sidney St., Cambridge, Massachusetts on Tuesday, November 12, 2002, at 10:00 a.m., Boston time, and at any adjournments thereof.

PLEASE FILL IN REVERSE SIDE AND MAIL IN THE ENCLOSED ENVELOPE

-FOLD AND DETACH HERE-

THE SHARES REPRESENTED HEREBY WILL BE VOTED AS DIRECTED HEREIN. IF NO DIRECTION IS INDICATED, SUCH SHARES WILL BE VOTED FOR ITEM 1 and AGAINST ITEM 2.

Please mark ☐ your votes as indicated in this example

Item 1. Election of Directors:

01 Mitchel Sayare
02 Walter A. Blättler
03 David W. Carter

04 Michael R. Eisenson
05 Stuart F. Feiner
06 Mark Skaletsky

FOR ALL NOMINEES
LISTED ABOVE
(except those
crossed out)
☐

WITHHOLD
AUTHORITY
to vote for all
nominees
☐

Item 2. Shareholder Proposal: Amendment of the Company's Articles of Organization to decrease from 75,000,000 shares to 50,000,000 shares the aggregate number of shares of Common Stock authorized to be issued by the Company.

FOR	AGAINST	ABSTAIN
☐	☐	☐

In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournments thereof.

I plan to attend the meeting ☐

This proxy may be revoked in writing or any time prior to the voting thereof.

Please date and sign exactly as name appears on this card. Joint owners should each sign. Please give full title when signing as executor, administrator, trustee, attorney, guardian for a minor, etc. Signatures for corporations and partnerships should be in the corporate or firm name by a duly authorized person. Please return this proxy promptly in the enclosed envelope.

Signature

Date

Signature

Date

-FOLD AND DETACH HERE-

**Vote by Internet or Telephone or Mail
24 Hours a Day, 7 Days a Week**

**Internet and telephone voting is available through 4PM Eastern Time
the business day prior to annual meeting day.**

**Your Internet or telephone vote authorizes the named proxies to vote your shares in the same manner as if you
marked, signed and returned your proxy card.**

Internet

<http://www.eproxy.com/imgn>

Use the Internet to vote your proxy. Have your proxy card in hand when you access the web site. You will be prompted to enter your control number, located in the box below, to create and submit an electronic ballot.

OR

Telephone

1-800-435-6710

Use any touch-tone telephone to vote your proxy. Have your proxy card in hand when you call. You will be prompted to enter your control number, located in the box below, and then follow the directions given.

OR

Mail

Mark, sign and date your proxy card and return it in the enclosed postage-paid envelope.

**If you vote your proxy by Internet or by telephone,
you do NOT need to mail back your proxy card.**

QuickLinks

[SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#)

[INFORMATION ABOUT THE COMPANY'S DIRECTORS AND CURRENT EXECUTIVE OFFICERS](#)

[OPTION GRANTS IN LAST FISCAL YEAR](#)

[COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION](#)

[REPORT OF AUDIT COMMITTEE](#)

[INDEPENDENT AUDITORS](#)

[SHAREHOLDER PROPOSAL: AMENDMENT OF THE COMPANY'S ARTICLES OF ORGANIZATION TO DECREASE FROM 75,000,000 SHARES TO 50,000,000 SHARES THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED TO BE ISSUED BY THE COMPANY \(Notice Item 2\)](#)

[SHAREHOLDER PROPOSALS AND OTHER MATTERS](#)

[IMMUNOGEN, INC. Charter of the Audit Committee of the Board of Directors, as Amended](#)